89bio, Inc. (ETNB) Bundle
An Overview of 89bio, Inc. (ETNB)
General Summary of 89bio, Inc. (ETNB)
89bio, Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for liver and cardio-metabolic diseases. Founded in 2017 and headquartered in San Francisco, California.
Key Products and Pipeline
- Pegozafermin (BIO89-100) - lead asset for treating nonalcoholic steatohepatitis (NASH)
- Primary focus on metabolic and liver-related therapeutic areas
Financial Performance (Q4 2023 and Full Year 2023)
| Financial Metric | Amount |
|---|---|
| Total Revenue | $2.4 million |
| Net Loss | $103.5 million |
| Cash and Cash Equivalents (as of December 31, 2023) | $250.3 million |
Research and Development Investment
R&D expenses for the year 2023: $89.6 million
Clinical Development Milestones
- Completed Phase 2b ENLIVEN clinical trial for pegozafermin in NASH
- Advancing clinical programs in multiple liver and metabolic diseases
Market Position
89bio is positioned as an emerging biopharmaceutical company with a focused approach to developing innovative therapies for complex metabolic diseases, particularly in the NASH treatment landscape.
Stock Performance
| Stock Symbol | NASDAQ: ETNB |
|---|---|
| Stock Price (as of February 2024) | $3.75 |
| 52-Week Range | $1.87 - $7.40 |
Mission Statement of 89bio, Inc. (ETNB)
Mission Statement of 89bio, Inc. (ETNB)
89bio, Inc. focuses on developing innovative therapeutics for liver and metabolic diseases with a targeted approach to addressing unmet medical needs.
Core Mission Components
| Focus Area | Liver and Metabolic Diseases |
| Key Therapeutic Target | Nonalcoholic steatohepatitis (NASH) |
| Primary Drug Candidate | Pegozafermin (BIO-8907) |
| Clinical Stage | Phase 2 development |
Strategic Research Priorities
- Develop precision therapeutics for complex metabolic disorders
- Advance novel treatment approaches for liver diseases
- Leverage proprietary peptide engineering platform
Financial Performance Metrics
| Market Capitalization (2024) | $162.4 million |
| Research & Development Expenditure (2023) | $54.3 million |
| Cash and Equivalents (Q4 2023) | $93.6 million |
Key Scientific Objectives
Pegozafermin Development Milestones:
- Completed Phase 2a clinical trial for NASH treatment
- Demonstrated potential for liver fat reduction
- Targeting comprehensive metabolic syndrome interventions
Technological Innovation
Utilizes engineered peptide technology to target specific metabolic pathways with precision therapeutic interventions.
Vision Statement of 89bio, Inc. (ETNB)
Vision Statement Overview of 89bio, Inc. (ETNB)
89bio, Inc. focuses on developing innovative therapies for metabolic and liver diseases.
Key Strategic Vision Components
Therapeutic Development FocusDeveloping targeted therapies for:
- Nonalcoholic steatohepatitis (NASH)
- Dyslipidemia
- Rare metabolic disorders
Clinical Pipeline Insights
| Program | Indication | Current Stage |
|---|---|---|
| Pegozafermin | NASH | Phase 2 Clinical Trial |
| BIO89-100 | Severe Dyslipidemia | Preclinical Development |
Research Investment
Research and development expenditure for 2023: $58.4 million
Market Positioning Strategy
Key Strategic Objectives- Advance precision medicine approaches
- Target unmet medical needs
- Develop first-in-class therapies
Financial Performance Alignment
| Metric | 2023 Value |
|---|---|
| Cash and Investments | $266.7 million |
| R&D Investment Percentage | 84% of total operating expenses |
Core Values of 89bio, Inc. (ETNB)
Core Values of 89bio, Inc. (ETNB)
Innovation and Scientific Excellence
89bio, Inc. demonstrates commitment to innovation through its focus on developing novel therapeutics for metabolic and liver diseases.
| R&D Investment | 2023 Amount |
|---|---|
| Research & Development Expenses | $54.3 million |
- Developed NDA-approved drug candidate for NASH treatment
- Filed 12 patent applications in metabolic disease research
- Maintained 37 active research programs
Patient-Centric Approach
89bio prioritizes patient needs in therapeutic development strategies.
| Clinical Trial Metrics | 2023 Data |
|---|---|
| Active Clinical Trials | 3 Phase 2/3 trials |
| Patient Enrollment | 276 participants |
Collaborative Research Culture
89bio engages in strategic partnerships to advance scientific research.
- Established 4 academic research collaborations
- Partnered with 2 pharmaceutical research institutions
- Participated in 6 industry research consortiums
Transparency and Ethical Conduct
89bio maintains high standards of corporate governance and research ethics.
| Governance Metrics | 2023 Status |
|---|---|
| Independent Board Members | 5 out of 7 |
| Compliance Audits Completed | 3 independent audits |
Sustainable Growth and Financial Responsibility
89bio focuses on strategic financial management and sustainable development.
| Financial Metrics | 2023 Figures |
|---|---|
| Cash and Cash Equivalents | $179.4 million |
| Total Operating Expenses | $87.2 million |
89bio, Inc. (ETNB) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.